These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 27482972)

  • 1. The Prevalence of Nodular Regenerative Hyperplasia in Inflammatory Bowel Disease Patients Treated with Thioguanine Is Not Associated with Clinically Significant Liver Disease.
    van Asseldonk DP; Jharap B; Verheij J; den Hartog G; Westerveld DB; Becx MC; Russel MG; Engels LG; de Jong DJ; Witte BI; Mulder CJ; van Nieuwkerk CM; Bloemena E; de Boer NK; van Bodegraven AA
    Inflamm Bowel Dis; 2016 Sep; 22(9):2112-20. PubMed ID: 27482972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 6-thioguanine associated nodular regenerative hyperplasia in patients with inflammatory bowel disease may induce portal hypertension.
    Ferlitsch A; Teml A; Reinisch W; Ulbrich G; Wrba F; Homoncik M; Gangl A; Peck-Radosavljevic M; Vogelsang H
    Am J Gastroenterol; 2007 Nov; 102(11):2495-503. PubMed ID: 17894846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nodular Regenerative Hyperplasia of the Liver in Patients with IBD Treated with Allopurinol-Thiopurine Combination Therapy.
    Seinen ML; van Asseldonk DP; de Boer NK; Bouma G; van Nieuwkerk CM; Mulder CJ; Bloemena E; van Bodegraven AA
    Inflamm Bowel Dis; 2017 Mar; 23(3):448-452. PubMed ID: 28151736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Limited relevance and progression of histological alterations in the liver during thioguanine therapy in inflammatory bowel disease patients.
    van Asseldonk DP; Simsek M; de Boer NKH; Jharap B; Bloemena E; den Hartog G; Westerveld DB; Becx MC; Russel MG; Lissenberg-Witte BI; van Nieuwkerk CM; Mulder CJJ; Verheij J; van Bodegraven AA
    Scand J Gastroenterol; 2019 Jun; 54(6):753-760. PubMed ID: 31203688
    [No Abstract]   [Full Text] [Related]  

  • 5. A systematic survey evaluating 6-thioguanine-related hepatotoxicity in patients with inflammatory bowel disease.
    Teml A; Schwab M; Hommes DW; Almer S; Lukas M; Feichtenschlager T; Florin T; Seiderer J; Petritsch W; Bokemeyer B; Kreisel W; Herrlinger KR; Knoflach P; Bonaz B; Klugmann T; Herfarth H; Pedarnig N; Reinisch W
    Wien Klin Wochenschr; 2007; 119(17-18):519-26. PubMed ID: 17943403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multicenter assessment of liver toxicity by MRI and biopsy in IBD patients on 6-thioguanine.
    Seiderer J; Zech CJ; Reinisch W; Lukas M; Diebold J; Wrba F; Teml A; Chalupna P; Stritesky J; Schoenberg SO; Schima W; Göke B; Ochsenkühn T
    J Hepatol; 2005 Aug; 43(2):303-9. PubMed ID: 15964660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 6-thioguanine can cause serious liver injury in inflammatory bowel disease patients.
    Dubinsky MC; Vasiliauskas EA; Singh H; Abreu MT; Papadakis KA; Tran T; Martin P; Vierling JM; Geller SA; Targan SR; Poordad FF
    Gastroenterology; 2003 Aug; 125(2):298-303. PubMed ID: 12891528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Absence of nodular regenerative hyperplasia after low-dose 6-thioguanine maintenance therapy in inflammatory bowel disease patients.
    de Boer NK; Zondervan PE; Gilissen LP; den Hartog G; Westerveld BD; Derijks LJ; Bloemena E; Engels LG; van Bodegraven AA; Mulder CJ
    Dig Liver Dis; 2008 Feb; 40(2):108-13. PubMed ID: 18083079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toxicity of 6-thioguanine: no hepatotoxicity in a series of IBD patients treated with long-term, low dose 6-thioguanine. Some evidence for dose or metabolite level dependent effects?
    Gilissen LP; Derijks LJ; Driessen A; Bos LP; Hooymans PM; Stockbrügger RW; Engels LG
    Dig Liver Dis; 2007 Feb; 39(2):156-9. PubMed ID: 17188950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence of nodular regenerative hyperplasia in inflammatory bowel disease patients treated with azathioprine.
    Seksik P; Mary JY; Beaugerie L; Lémann M; Colombel JF; Vernier-Massouille G; Cosnes J
    Inflamm Bowel Dis; 2011 Feb; 17(2):565-72. PubMed ID: 20848502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review article: the association between nodular regenerative hyperplasia, inflammatory bowel disease and thiopurine therapy.
    Musumba CO
    Aliment Pharmacol Ther; 2013 Nov; 38(9):1025-37. PubMed ID: 24099468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatotoxicity during 6-thioguanine treatment in inflammatory bowel disease and childhood acute lymphoblastic leukaemia: A systematic review.
    Toksvang LN; Schmidt MS; Arup S; Larsen RH; Frandsen TL; Schmiegelow K; Rank CU
    PLoS One; 2019; 14(5):e0212157. PubMed ID: 31125338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early hepatic nodular hyperplasia and submicroscopic fibrosis associated with 6-thioguanine therapy in inflammatory bowel disease.
    Geller SA; Dubinsky MC; Poordad FF; Vasiliauskas EA; Cohen AH; Abreu MT; Tran T; Martin P; Vierling JM; Targan SR
    Am J Surg Pathol; 2004 Sep; 28(9):1204-11. PubMed ID: 15316320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Course of Nodular Regenerative Hyperplasia in Thiopurine Treated Inflammatory Bowel Disease Patients.
    Simsek M; Meijer B; Ramsoekh D; Bouma G; van der Wouden EJ; den Hartog B; de Vries AC; Hoentjen F; Dijkstra G; de Boer SY; Jansen JM; van der Meulen AE; Beukers R; Brink MA; Steinhauser T; Oldenburg B; Gilissen LP; Naber TH; Verhagen MA; de Boer NKH; Mulder CJJ;
    Clin Gastroenterol Hepatol; 2019 Feb; 17(3):568-570. PubMed ID: 29775790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Splitting a therapeutic dose of thioguanine may avoid liver toxicity and be an efficacious treatment for severe inflammatory bowel disease: a 2-center observational cohort study.
    Pavlidis P; Ansari A; Duley J; Oancea I; Florin T
    Inflamm Bowel Dis; 2014 Dec; 20(12):2239-46. PubMed ID: 25230165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence and clinical significance of nodular regenerative hyperplasia in liver biopsies.
    Barge S; Grando V; Nault JC; Broudin C; Beaugrand M; Ganne-Carrié N; Roulot D; Ziol M
    Liver Int; 2016 Jul; 36(7):1059-66. PubMed ID: 26415006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nodular regenerative hyperplasia in patients with inflammatory bowel disease treated with azathioprine.
    Vernier-Massouille G; Cosnes J; Lemann M; Marteau P; Reinisch W; Laharie D; Cadiot G; Bouhnik Y; De Vos M; Boureille A; Duclos B; Seksik P; Mary JY; Colombel JF
    Gut; 2007 Oct; 56(10):1404-9. PubMed ID: 17504943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic liver disease related to 6-thioguanine in children with acute lymphoblastic leukaemia.
    De Bruyne R; Portmann B; Samyn M; Bansal S; Knisely A; Mieli-Vergani G; Dhawan A
    J Hepatol; 2006 Feb; 44(2):407-10. PubMed ID: 16226335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Critical assessment of thioguanine treatment for inflammatory bowel diseases: Is it time to rehabilitate this treatment?
    Movva R; Haywood A; Khan SA; Florin TH; Oancea I
    J Dig Dis; 2017 Sep; 18(9):529-536. PubMed ID: 28834232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 6-Thioguanine treatment in inflammatory bowel disease: a critical appraisal by a European 6-TG working party.
    de Boer NK; Reinisch W; Teml A; van Bodegraven AA; Schwab M; Lukas M; Ochsenkühn T; Petritsch W; Knoflach P; Almer S; van der Merwe SW; Herrlinger KR; Seiderer J; Vogelsang H; Mulder CJ;
    Digestion; 2006; 73(1):25-31. PubMed ID: 16493198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.